IL7 and melanoma: Subsequently, they developed an LX/IL-7-based autologous tumor vaccine by loading irradiated B16-F10 murine melanoma or EL-4 murine lymphoma cells with LX/IL-7 (i.e., B16-LX/IL-7 or EL4-LX/IL7) and tested its antitumor efficacy, prophylactically and therapeutically [28].